MIRV, an FRα-targeted ADC, has shown significant efficacy in FRα-high PROC, defined as ≥ 75% tumor cells with ≥ 2 + immunohistochemistry (IHC) staining. This evidence concerns the gene FOLR1 and neoplasm.